Aliases & Classifications for Alopecia

MalaCards integrated aliases for Alopecia:

Name: Alopecia 12 74 58 29 6 44 15 71

Classifications:

Orphanet: 58  
Rare skin diseases


External Ids:

Disease Ontology 12 DOID:987
ICD9CM 34 704.0
MeSH 44 D000505
NCIt 50 C50575
SNOMED-CT 67 270504008
ICD10 32 L65.9
UMLS via Orphanet 72 C0002170
Orphanet 58 ORPHA79364
UMLS 71 C0002170

Summaries for Alopecia

Disease Ontology : 12 A hypotrichosis that is characterized by a loss of hair from the head or body.

MalaCards based summary : Alopecia is related to alopecia universalis congenita and alopecia-intellectual disability syndrome, and has symptoms including pruritus and exanthema. An important gene associated with Alopecia is FOXN1 (Forkhead Box N1). The drugs Bimatoprost and Hydroxychloroquine have been mentioned in the context of this disorder. Affiliated tissues include Hair, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Hair loss, also known as alopecia or baldness, refers to a loss of hair from part of the head or body.... more...

Related Diseases for Alopecia

Diseases in the Alopecia family:

Alopecia, Congenital

Diseases related to Alopecia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1063)
# Related Disease Score Top Affiliating Genes
1 alopecia universalis congenita 33.2 HR FOXN1 AIRE
2 alopecia-intellectual disability syndrome 32.7 LSS AHSG
3 alopecia-mental retardation syndrome 32.4 MBTPS2 LSS AHSG
4 hypotrichosis 31.8 LSS HR GJA1 DCAF17
5 hypotrichosis 11 31.7 RIN2 RBM28 DCAF17
6 keratosis 31.2 MBTPS2 KRT14 GJA1 DSP
7 skin disease 31.1 VDR TP63 KRT14 GJA1 DSP
8 hair disease 30.6 MBTPS2 KRT14 FOXN1 DSP DCAF17 AR
9 palmoplantar keratosis 30.6 SASH1 GJA1 DSP
10 ectodermal dysplasia 30.6 TP63 KRT14 GJA1 DSP AIRE
11 thymoma 30.4 TP63 DSP AIRE
12 acrocephalopolysyndactyly type iii 30.2 RBM28 DCAF17
13 basal cell carcinoma 30.1 VDR TP63 KRT14 AR
14 angular cheilitis 29.9 MBTPS2 AIRE
15 alopecia areata 11.9
16 alopecia, androgenetic, 1 11.7
17 t-cell immunodeficiency, congenital alopecia, and nail dystrophy 11.7
18 palmoplantar keratoderma and congenital alopecia 1 11.6
19 palmoplantar keratoderma and congenital alopecia 2 11.6
20 androgenic alopecia 11.5
21 frontal fibrosing alopecia 11.5
22 woodhouse-sakati syndrome 11.5
23 alopecia totalis 11.5
24 mandibulofacial dysostosis with alopecia 11.5
25 central centrifugal cicatricial alopecia 11.5
26 alopecia, neurologic defects, and endocrinopathy syndrome 11.5
27 ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis 11.4
28 alopecia-mental retardation syndrome 1 11.4
29 gapo syndrome 11.4
30 cerebral arteriopathy, autosomal recessive, with subcortical infarcts and leukoencephalopathy 11.4
31 alopecia, psychomotor epilepsy, pyorrhea, and mental subnormality 11.4
32 diffuse alopecia areata 11.4
33 macs syndrome 11.4
34 alopecia-mental retardation syndrome 4 11.4
35 polyposis, skin pigmentation, alopecia, and fingernail changes 11.3
36 vitamin d-dependent rickets, type 2a 11.3
37 ifap syndrome 1, with or without bresheck syndrome 11.3
38 cancer, alopecia, pigment dyscrasia, onychodystrophy, and keratoderma 11.3
39 alopecia-mental retardation syndrome 2 11.3
40 alopecia-contractures-dwarfism-intellectual disability syndrome 11.3
41 crandall syndrome 11.3
42 alopecia-epilepsy-oligophrenia syndrome of moynahan 11.3
43 johnson neuroectodermal syndrome 11.3
44 alopecia-contractures-dwarfism mental retardation syndrome 11.3
45 alopecia areata 1 11.2
46 frontonasal dysplasia 2 11.2
47 satoyoshi syndrome 11.2
48 gomez-lopez-hernandez syndrome 11.2
49 odonto onycho dysplasia with alopecia 11.2
50 follicular mucinosis 11.2

Graphical network of the top 20 diseases related to Alopecia:



Diseases related to Alopecia

Symptoms & Phenotypes for Alopecia

UMLS symptoms related to Alopecia:


pruritus, exanthema

GenomeRNAi Phenotypes related to Alopecia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.7 GJA1 SASH1
2 Decreased viability GR00249-S 9.7 LSS TP63
3 Decreased viability GR00381-A-1 9.7 LSS
4 Decreased viability GR00386-A-1 9.7 FOXN1 LSS UQCRFS1 VDR
5 Decreased viability GR00402-S-2 9.7 DSP EDNRA
6 Increased CFP-tsO45G cell surface transport GR00360-A-1 8.32 GJA1

MGI Mouse Phenotypes related to Alopecia:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.39 AHSG AIRE AR AUTS2 DSP EDNRA
2 cellular MP:0005384 10.35 AR AUTS2 DCAF17 DSP EDNRA FOXN1
3 mortality/aging MP:0010768 10.28 AIRE AR AUTS2 DSP EDNRA FOXN1
4 cardiovascular system MP:0005385 10.27 AR AUTS2 DSP EDNRA FOXN1 GJA1
5 endocrine/exocrine gland MP:0005379 10.22 AIRE AR AUTS2 EDNRA FOXN1 GJA1
6 immune system MP:0005387 10.22 AIRE AR DSP EDNRA FOXN1 GJA1
7 integument MP:0010771 10.2 AR DSP EDNRA FOXN1 GJA1 HR
8 embryo MP:0005380 10.19 AR AUTS2 DSP EDNRA FOXN1 GJA1
9 craniofacial MP:0005382 10.16 AR DSP EDNRA GJA1 HR KRT14
10 digestive/alimentary MP:0005381 10.15 AIRE AR DSP EDNRA HR KRT14
11 hearing/vestibular/ear MP:0005377 10.1 AHSG EDNRA FOXN1 GJA1 HR KRT14
12 nervous system MP:0003631 10.06 AIRE AR AUTS2 DSP EDNRA FOXN1
13 muscle MP:0005369 10.01 AHSG AR DSP EDNRA FOXN1 GJA1
14 neoplasm MP:0002006 9.91 AIRE AR AUTS2 FOXN1 HR KRT14
15 reproductive system MP:0005389 9.81 AIRE AR DCAF17 FOXN1 GJA1 HR
16 pigmentation MP:0001186 9.65 AR FOXN1 HR KRT14 UQCRFS1
17 skeleton MP:0005390 9.61 AHSG AR AUTS2 EDNRA FOXN1 GJA1
18 vision/eye MP:0005391 9.28 AIRE DSP EDNRA FOXN1 GJA1 HR

Drugs & Therapeutics for Alopecia

Drugs for Alopecia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 264)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
2
Hydroxychloroquine Approved Phase 4 118-42-3 3652
3
Tofacitinib Approved, Investigational Phase 4 477600-75-2
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
5 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
6 Orange Approved Phase 4
7
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
8
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
9
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
10
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
11
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
12
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
13
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
14
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
15
Fluocinonide Approved, Investigational Phase 4 356-12-7 9642
16
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
17
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
18
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
19
Cetirizine Approved Phase 4 83881-51-0 2678
20
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
21
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
22
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
23
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
24 Dermatologic Agents Phase 4
25 Ophthalmic Solutions Phase 4
26 Antiprotozoal Agents Phase 4
27 Antimalarials Phase 4
28 Protein Kinase Inhibitors Phase 4
29 interferons Phase 4
30 Protective Agents Phase 4
31 Gastrointestinal Agents Phase 4
32 Methylprednisolone Acetate Phase 4
33 Neuroprotective Agents Phase 4
34 Antineoplastic Agents, Hormonal Phase 4
35 Antiemetics Phase 4
36 Anesthetics Phase 4
37 Sodium Channel Blockers Phase 4
38 Anesthetics, Local Phase 4
39 Anti-Arrhythmia Agents Phase 4
40 Respiratory System Agents Phase 4
41 Anti-Asthmatic Agents Phase 4
42 Betamethasone sodium phosphate Phase 4
43 Betamethasone-17,21-dipropionate Phase 4
44 Betamethasone benzoate Phase 4
45 Betamethasone Valerate Phase 4 2152-44-5
46 Analgesics, Non-Narcotic Phase 4
47 Anti-Inflammatory Agents, Non-Steroidal Phase 4
48 Analgesics Phase 4
49 N-monoacetylcystine Phase 4
50 Neurotransmitter Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 325)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in the Treatment of Central Centrifugal Cicatricial Alopecia Unknown status NCT01111981 Phase 4 Clobetasol Propionate 0.05% Emollient Foam
2 Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial Unknown status NCT02999737 Phase 4
3 Cryotherapy Versus Intralesional Corticosteroid Injection In Treatment Of Alopecia Areata: Trichoscopic Evaluation Unknown status NCT03473600 Phase 4 Triamcinolone acetonide injection
4 Open Label Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia Unknown status NCT03422640 Phase 4 Apremilast
5 Open Label Study of Hydroxychloroquine for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
6 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4 methylprednisolone sodium succinate;methylprednisolone sodium succinate;methylprednisolone sodium succinate
7 Aldara for the Treatment of Extensive Alopecia Areata Completed NCT00177021 Phase 4 Aldara Cream 5%
8 Phenotype and Cytokine Production Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Aldara 5% Cream Using Flow Cytometry Completed NCT00176943 Phase 4 Aldara Cream 5%
9 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Completed NCT01023841 Phase 4 bimatoprost ophthalmic solution 0.03%;Vehicle Sterile Solution
10 Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata Completed NCT03800979 Phase 4 Tofacitinib
11 Combined Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata A Randomized Controlled Trial Completed NCT03535233 Phase 4 Triamcinolone Acetonide;Minoxidil 5 % Topical Spray;clobetasol propionate
12 Perifollicular Nerves in Alopecia Areata: Response to Topical Capsaicin Completed NCT00176969 Phase 4 Capsaicin
13 A Randomized Comparative Study of Efficacy and Safety of Topical Latanoprost Versus Topical Corticosteroid in the Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4 Topical latanoprost 0.005%;Topical betamethasone 0.05%
14 The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial Completed NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
15 Minoxidil in Treatment of Androgenetic Alopecia Completed NCT04090801 Phase 4 Topical minoxidil 5% in 90% ethanol and 5% propylene glycol;Topical minoxidil 5% in pure ethanol alone
16 Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study Recruiting NCT04207931 Phase 4 Topical steroid class I-II;Triamcinolone Acetonide;Doxycyline;Minoxidil
17 Efficacy of Fractional CO2 Laser Alone and as Transepidermal Drug Delivery for Different Modalities of Treatment in Alopecia Areata Recruiting NCT04003376 Phase 4 Triamcinolone Acetonide 10mg/mL;vitamin D solution
18 An Open-label Pilot Study to Investigate the Efficacy of Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) Recruiting NCT03521687 Phase 4 Apremilast
19 the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial Recruiting NCT03388840 Phase 4
20 Efficacy and Tolerability of N-Acetyl- Cysteine for Treatment of The Early-onset Androgenetic Alopecia in Men Recruiting NCT04209803 Phase 4 Minoxidil 5% topically and oral NAC 600 mg
21 Modified SALT Score for Assessment of Alopecia Areata Recruiting NCT04412148 Phase 4 Triamcinolone Acetonide
22 Does Carboxytherapy Play a Role in Alopecia Areata Either Solely or in Combination? Comparative Study for Treatment of Alopecia Areata Using Carboxytherapy and Intralesional Steroids Active, not recruiting NCT04228029 Phase 4 Intralesional Steroid Injection
23 Topical Cetirizine Gel Versus Minoxidil 5% Gel in Treatment of Androgenetic Alopecia Not yet recruiting NCT04293822 Phase 4 Cetirizine;Minoxidil
24 A Phase 4 Multicenter, Randomized, Placebo Controlled Trial of 3 Doses of Intralesional Triamcinolone (KENALOG®) In the Treatment of Mild to Moderate Patch Type Alopecia Areata Terminated NCT01898806 Phase 4 Intralesional Triamcinolone 2.5 mg/ml;Intralesional Triamcinolone 5 mg/ml;Intralesional Triamcinolone 10 mg/ml;Intralesional Saline
25 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
26 BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA Unknown status NCT01655108 Phase 3 Minoxidil;Saline
27 Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM) Completed NCT01590238 Phase 3
28 The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Completed NCT00997815 Phase 2, Phase 3 Botulinum toxin A;Normal saline injection
29 Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
30 RANDOMIZED DOUBLE-BLIND STUDY MULTICENTRIQUE TESTING THE EFFICIENCY OF the METHOTREXATE AT PATIENTS AFFECTED BY GRAVE PELADE (METHOTREXATE VERSUS PLACEBO WITH SECONDARY TREATMENT BY METHOTREXATE and PREDNISONE) Completed NCT02037191 Phase 3 Methotrexate;Placebo
31 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia) Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
32 A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
33 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625) Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
34 A Randomized Controlled Trial of Clobetasol Propionate 0.05% Cream Versus Hydrocortisone 1% Cream in Children With Alopecia Areata Completed NCT01453686 Phase 3 Hydrocortisone 1%;Clobetasol Propionate 0.05%
35 A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
36 A Double-Blind, Randomized, Placebo-Controlled Trial of the Efficacy and Safety of 5 Percent Minoxidil Foam in the Treatment of Androgenetic Alopecia in Males Completed NCT00151515 Phase 3 minoxidil
37 A Two Stage Phase II Randomized Bilateral Comparison of Topical Targretin® Gel 1% in Alopecia Areata Completed NCT00063076 Phase 2, Phase 3 Targretin Gel 1%
38 Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
39 TREg Activation in the Treatment of the PELADE (Alopecia Areata). Double Blind Randomized Placebo Controlled Comparative Study Using Low Doses of IL2 Completed NCT02557074 Phase 3 IL2;placebo
40 A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
41 An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V) Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
42 A Prospective, Randomized, Controlled, Double-Blind Study That Evaluates the Safety and Efficacy of Three Active REVIAN Caps Versus a Non-Active REVIAN Cap (Sham) in Participants With Pattern Hair Loss (Androgenic Alopecia) Completed NCT04019795 Phase 3
43 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% & 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia Completed NCT03742518 Phase 2, Phase 3 Topical SM04554 solution;Topical SM04554 solution;Topical vehicle solution
44 Evaluating the Efficacy of Topical Herbal Solution on the Treatment of Androgenetic Alopecia and Comparison With Minoxidil 5%: A Double-Blind, Randomized, Clinical Trial Study Completed NCT03753113 Phase 3 Topical Herbal Solution;Topical Minoxidil 5%
45 A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness Completed NCT03004469 Phase 3 P-3074;Finasteride;P-3074 Vehicle;Finasteride Placebo
46 Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume Completed NCT00958750 Phase 3 minoxidil
47 A Randomized Phase II Trial Investigating the Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment
48 A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM. Completed NCT00916409 Phase 3 Temozolomide
49 The Derm Aid Study Completed NCT04249128 Phase 3
50 Comparative Study of Scalp Cooling System and Chemical Cold Cap on Prevention of Chemotherapy-induced Alopecia in Women With Breast Cancer Recruiting NCT03711877 Phase 3

Search NIH Clinical Center for Alopecia

Inferred drug relations via UMLS 71 / NDF-RT 51 :


D-BIOTIN
Finasteride
Minoxidil

Cochrane evidence based reviews: alopecia

Genetic Tests for Alopecia

Genetic tests related to Alopecia:

# Genetic test Affiliating Genes
1 Alopecia 29

Anatomical Context for Alopecia

MalaCards organs/tissues related to Alopecia:

40
Prostate, Skin, Ovary, Breast, T Cells, Lung, Bone Marrow
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Alopecia:
# Tissue Anatomical CompartmentCell Relevance
1 Hair Hair Follicle Fetal Hair Placode Cells Affected by disease
2 Hair Hair Follicle Fetal Matrix Cells Affected by disease
3 Hair Dermal Papilla Guard Dermal Papilla Cells Affected by disease
4 Hair Hair Follicle Primary Hair Placode Cells Affected by disease

Publications for Alopecia

Articles related to Alopecia:

(show top 50) (show all 17530)
# Title Authors PMID Year
1
Trichoscopic findings of discoid lupus erythematosus alopecia: A cross-sectional study. 61
32502590 2021
2
Risk factors for frontal fibrosing alopecia: A case-control study in a multiracial population. 61
32835739 2021
3
Impact of cyclosporin treatment on health-related quality of life of patients with alopecia areata. 61
31389731 2021
4
Putative therapeutic mechanisms of simvastatin in the treatment of alopecia areata. 61
32278796 2021
5
Drug-induced alopecia areata? 61
32681530 2021
6
An open-label study evaluating the efficacy of abatacept in alopecia areata. 61
33045294 2021
7
Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. 61
31403367 2021
8
Oral minoxidil treatment for hair loss: A review of efficacy and safety. 61
32622136 2021
9
Cutaneous Vasculopathy and Pulmonary Thromboembolism in an Unstable Diabetic Cat. 61
33115690 2021
10
Patients' satisfaction following laparoscopic cornuectomy for removal of hysteroscopic sterilization devices. 61
33049363 2021
11
Development, validation, and application of an RP-HPLC method for concurrent quantification of Minoxidil and Finasteride in a topical solution for hair regrowth. 61
33091398 2021
12
Treatment of sarcoptic and chorioptic mange in an alpaca (Vicugna pacos) herd with a combination of topical amitraz and subcutaneous ivermectin. 61
32814497 2021
13
Low-dose oral minoxidil for treating alopecia: A 3-year North American retrospective case series. 61
33098962 2021
14
Epidemiologic and clinical features of pattern III frontal fibrosing alopecia (pseudo fringe type): A multicenter series of 38 patients. 61
32497694 2021
15
Coming full circle (almost): Low dose oral minoxidil for alopecia. 61
33421481 2021
16
"Fake news" in dermatology. Results from an observational, cross-sectional study. 61
33095467 2021
17
Association of breast and colorectal cancer in patients with central centrifugal cicatricial alopecia: A retrospective, cross-sectional pilot study. 61
33470208 2021
18
Are drug treatment strategies really effective against alopecia areata? 61
33280456 2021
19
Patient Perspectives of the Cumulative Life Course Impairment of Alopecia Areata. 61
33548059 2021
20
The Possible Linkage of Granzyme B-Producing Skin T Cells with the Disease Prognosis of Alopecia Areata. 61
32621823 2021
21
Efficacy and predictive factors of cyclosporine a in alopecia areata: a systematic review with meta-analysis. 61
33555953 2021
22
Flag sign: the trichoscopic feature of white hair phenomenon in alopecia areata. 61
32762090 2021
23
Prevalence of cardiac and metabolic diseases among patients with alopecia areata. 61
32780884 2021
24
Experience with oral tofacitinib in severe alopecia areata with different clinical responses. 61
33533091 2021
25
Alopecia areata and novel biologic agents: report of four cases and future directions. 61
33565623 2021
26
Alopecia Areata Related Paradoxical Reactions in Patients on Dupilumab Therapy: A Systematic Review. 61
33586473 2021
27
Lesson to Learn From Cellular infiltrate in Scalp Biopsy of Alopecia Areata. 61
33606369 2021
28
Impact of alopecia areata on subsequent pregnancy rate: A retrospective cohort study. 61
32790070 2021
29
Reply to ''Coexistence of frontal fibrosing alopecia and alopecia areata: 3 new cases and review of the literature'': plasmacytoid dendritic cell as possible link. 61
33590490 2021
30
The status and outcomes of registered clinical trials for JAK inhibitors in alopecia areata: are non-published trials being overlooked? 61
33608909 2021
31
Low-dose tacrolimus in treating neuromyelitis optica spectrum disorder. 61
33383362 2021
32
Quantifying the impact of braiding and combing on the integrity of natural African hair. 61
33605448 2021
33
Hair loss treatment information on Facebook: Content analysis and comparison with other online sources. 61
33174285 2021
34
Efficacy of Fluralaner in the treatment of sarcoptic mange (Sarcoptes scabiei) in 12 pet rabbits. 61
33548547 2021
35
Radiofrequency Microneedling: A Comprehensive and Critical Review. 61
33577211 2021
36
Paper 2. Epigallocatechin Gallate and Tannic Acid Based Formulations of Finasteride for Dermal Administration and Chemoembolization. 61
33035538 2021
37
Artificial hair implantation for hair restoration. 61
33565339 2021
38
Platelet lysate: a promising candidate in regenerative medicine. 61
33543999 2021
39
Use of vibrating anesthetic device reduces the pain of mesotherapy injections: A randomized split-scalp study. 61
32640097 2021
40
miRNA microarray profiling in patients with androgenic alopecia and the effects of miR-133b on hair growth. 61
33290799 2021
41
Incidence and Factors Associated With Androgenetic Alopecia Among Transgender and Gender-Diverse Patients Treated With Masculinizing Hormone Therapy. 61
33566078 2021
42
Favorable effects of microneedling on long-standing androgenetic alopecia in an elderly man: A case report. 61
32500595 2021
43
Transcriptome profiling of pilosebaceous units in male androgenetic alopecia reveals altered junctional networks. 61
33607114 2021
44
The role of prostaglandins in androgenetic alopecia. 61
33528035 2021
45
Reply to: << The effect of platelet-rich plasma on female androgenetic alopecia: A randomized controlled trial >>. 61
33549654 2021
46
Low-Level Laser Therapy for Androgenetic Alopecia. 61
33130013 2021
47
Reply to Kim et al letter on "The effect of platelet-rich plasma on female androgenetic alopecia: A randomized controlled trial". 61
33549651 2021
48
[A new treatment for androgenetic alopecia : platelet-rich plasma injections]. 61
33543858 2021
49
Association of Fibrosis in Bulge Portion with Hair Follicle Miniaturization in Androgenetic Alopecia. 61
33539849 2021
50
Adenocarcinoma arising in the multiple heterotopic submucosal glands of the intestine in a Satoyoshi syndrome patient: A case report. 61
33333628 2021

Variations for Alopecia

ClinVar genetic disease variations for Alopecia:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SASH1 NM_015278.5(SASH1):c.1849G>A (p.Glu617Lys) SNV Likely pathogenic 156162 rs587781245 6:148855021-148855021 6:148533885-148533885
2 NDC80 GRCh37/hg19 18p11.32-11.31(chr18:1345040-3479168) copy number loss Uncertain significance 523239 18:1345040-3479168

Expression for Alopecia

Search GEO for disease gene expression data for Alopecia.

Pathways for Alopecia

GO Terms for Alopecia

Cellular components related to Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fascia adherens GO:0005916 8.62 GJA1 DSP

Biological processes related to Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.73 VDR TP63 FOXN1 AUTS2 AR AIRE
2 keratinocyte differentiation GO:0030216 9.33 TP63 FOXN1 DSP
3 epidermis development GO:0008544 9.26 TP63 KRT14 FOXN1 DSP
4 thymus epithelium morphogenesis GO:0097536 8.62 FOXN1 AIRE

Sources for Alopecia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....